Experience with peritoneal mesothelioma at the Milan National Cancer Institute

Table 1 Clinicopathologic variables with prognostic significance according to univariate (log-rank) and multivariate (Cox proportional hazard model) analyses

Variable	Overall survival			Progression-free survival
	Univariate	Multivariate		Univariate	Multivariate
	P value	HR (95% CI)	P value	P value	HR (95% CI)	P value
Sex	0.22			0.27
Age (< 52 yrvs≥52 yr)	0.93			0.49
Performance status (0vs1, 2, or 3)	0.43			0.05	0.29 (0.1-0.8)	0.02
Previous surgical score (0vs≥1)	0.78			0.11
Previous systemic CT	0.59			0.57
PCI (≥28vs< 28)	0.12			0.10
Completeness of cytoreduction (0/1vs2/3)a	0.01	8.6 (2.1-36.2)	0.00	0.08
IPHP drug schedule (CDDP + DXvsCDDP + MMC)	0.36			0.98
Histological subtype (epithelioidvsbiphasic)	0.09			0.07
Mitotic count(< 5vs≥5)	0.01	10.5 (1.9-55.2)	0.01	0.19	3.1 (1.1-8.8)	0.03
Nuclear grade (highvslow)	0.02			0.10

^a0/1, minimal residual disease or residual tumor < 2.5 mm; 2/3, residual tumor ≥ 2.5 mm. CI: Confidence interval; PCI: Peritoneal Cancer Index; IPHP: Intraperitoneal hyperthermic perfusion; CDDP: Cisplatin; DX: Doxorubicin; MMC: Mitomycin C; HPF: High-power field.